Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
5.26
-0.23 (-4.19%)
Apr 29, 2026, 3:05 PM EDT - Market open
Atossa Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -34.77 | -25.5 | -30.09 | -26.96 | -20.61 | |
| Depreciation & Amortization | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Loss (Gain) From Sale of Assets | - | 0.01 | - | - | - | |
| Loss (Gain) From Sale of Investments | - | 1.71 | 2.99 | - | - | |
| Stock-Based Compensation | 2.65 | 2.29 | 4.62 | 6.79 | 5.27 | |
| Other Operating Activities | - | - | - | 0 | - | |
| Change in Inventory | -0.98 | -0.61 | - | - | - | |
| Change in Accounts Payable | 3.61 | -0.13 | -2.16 | 1.25 | 0.13 | |
| Change in Other Net Operating Assets | -0.29 | 1.19 | 3.68 | -1.85 | -1.28 | |
| Operating Cash Flow | -29.76 | -21.03 | -20.94 | -20.76 | -16.47 | |
| Capital Expenditures | -0.02 | -0.02 | -0.01 | -0.03 | -0.01 | |
| Investment in Securities | - | - | - | -4.7 | - | |
| Investing Cash Flow | -0.02 | -0.02 | -0.01 | -4.73 | -0.01 | |
| Issuance of Common Stock | - | 3.67 | - | - | 113.88 | |
| Repurchase of Common Stock | - | - | -1.48 | - | -0.57 | |
| Financing Cash Flow | - | 3.67 | -1.48 | - | 113.3 | |
| Net Cash Flow | -29.79 | -17.38 | -22.43 | -25.49 | 96.82 | |
| Free Cash Flow | -29.79 | -21.05 | -20.96 | -20.79 | -16.48 | |
| Free Cash Flow Per Share | -3.46 | -2.51 | -2.49 | -2.46 | -2.11 | |
| Levered Free Cash Flow | -18.23 | -14.86 | -11.76 | -10.54 | -21.72 | |
| Unlevered Free Cash Flow | -18.23 | -14.86 | -11.76 | -10.54 | -21.72 | |
| Change in Working Capital | 2.35 | 0.45 | 1.52 | -0.6 | -1.16 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.